Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services
February 10 2020 - 8:00AM
Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug
development business of LabCorp® (NYSE: LH), a leading global life
sciences company, has selected Fluidigm’s CyTOF® technology and the
industry-leading Maxpar® Direct™ Immune Profiling Assay™ to develop
highly multiplexed immune profiling services.
Setting an industry first, high-multiplex mass
cytometry enables clinical researchers to simultaneously
profile more than 50 cell surface and intracellular parameters in a
single run. Ideal for use with panels comprising more than 20
parameters, mass cytometry simplifies high-parameter panel design
by using non-overlapping metal isotope tags that can be easily
distinguished in cells using CyTOF technology. Empowering clinical
researchers to deeply profile cell phenotypes and function with
robust reproducibility, mass cytometry has been used in more than
70 clinical trials and is trusted by academic medical centers,
pharmaceutical companies and research consortia worldwide.
“Providing greater insights from a patient sample has become
critical for our pharmaceutical clients to support the development
of complex and innovative new drugs,” said Vincent Drouillon, Vice
President Global Testing Services, Medical Affairs and Science at
Covance Clinical Trial Testing Solutions. “Fluidigm CyTOF
technology enables us to seamlessly provide our customers with an
exceptional level of multiplexing in cytometry.”
“Partnering with leading contract research organizations (CROs)
is a critical component of our growth strategy,” said Chris
Linthwaite, President and CEO of Fluidigm. “As utilization of mass
cytometry in early-stage clinical studies grows, pharma and biotech
customers require global service providers who can scale with them.
Covance is the perfect partner for commercializing
sophisticated biomarker discovery and clinical support
services. We are excited to collaborate with them to advance
the frontiers of science and health care.”
About FluidigmFluidigm (Nasdaq:FLDM) is an
industry-leading biotechnology tools provider with a vision to
improve life through comprehensive health insight. We focus on the
most pressing needs in translational and clinical research,
including cancer, immunology, and immunotherapy. Using proprietary
CyTOF and microfluidics technologies, we develop, manufacture, and
market multi-omic solutions to drive meaningful insights in health
and disease, identify biomarkers to inform decisions, and
accelerate the development of more effective therapies. Our
customers are leading academic, government, pharmaceutical,
biotechnology, and plant and animal research laboratories
worldwide. Together with them, we strive to increase the quality of
life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Immune
Profiling Assay and Maxpar are trademarks and/or registered
trademarks of Fluidigm Corporation in the United
States and/or other countries. Fluidigm products are provided
for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements for Fluidigm
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding market growth and
demand, and the anticipated benefits to customers of, and
applications for, Fluidigm products. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results,
including but not limited to risks relating to challenges inherent
in developing, manufacturing, launching, marketing, and selling new
products; potential product performance and quality issues;
intellectual property risks; competition; uncertainties in
contractual relationships; and reductions in research and
development spending or changes in budget priorities by customers.
Information on these and additional risks and uncertainties and
other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2018, and in its other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Contacts:
Fluidigm Media: Michaeline
BuntingSenior Director, Marketing 650 737
4190michaeline.bunting@fluidigm.com
Investors:Agnes LeeVice President, Investor
Relations650 416 7423agnes.lee@fluidigm.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024